Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab maintenance after concurrent chemoradiation for limited-stage small-cell lung cancer
jRCT2031230601Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Tarlatamab with Placebo (2 arms). Primary endpoints: Progression-free survival as determined by blinded independent central review and Overall survival over the whole trial. Started Feb 2024; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031230601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230601.